公告提醒：愛必信所有產(chǎn)品和服務(wù)僅用于科學(xué)研究，不用于臨床應(yīng)用及其他用途提供產(chǎn)品和服務(wù)（也不為任何個(gè)人提供產(chǎn)品和服務(wù)）!

抑制劑描述：

產(chǎn)品名稱：Apatinib Mesylate

產(chǎn)品別名：YN968D1

英文別名：YN968D1

靶點(diǎn)：VEGFR2 ,RET

CAS：1218779-75-9

純度：0.99

外觀：Powder

保存方法：store at -20℃ for one year（Powder）； in DMSO or others solvent store at 2-4℃ for two weeks, at -20℃ for six months.

描述：

Apatinib (YN968D1) is an orally bioavailable, selective VEGFR2 inhibitor with IC50 of 1 nM.

溶解性：DMSO：22 mg/mL (44.57 mM)

體外研究：

Apatinib (YN968D1) is a novel, orally bioavailable, selective inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits VEGFR2. Apatinib can also potently suppress the activities of Ret, c-kit and c-src with IC50 of 0.013 μM, 0.429 μM and 0.53 μM, respectively. Apatinib inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ. Apatinib significantly inhibits proliferation stimulated by 20 ng/mL VEGF (IC50 = 0.17μM). Apatinib effectively inhibits proliferation, migration and tube formation of human umbilical vein endothelial cells induced by FBS, and blocked the budding of rat aortic ring. Apatinib reverses ABCB1- and ABCG2-mediated MDR by inhibiting their transport function, but not by blocking the AKT or ERK1/2 pathway or downregulating ABCB1 or ABCG2 expression. Apatinib significantly potentiates the cytotoxicity of established ABCB1 and ABCG2 substrates and increased the accumulation of DOX and Rho 123 in ABCB1- or ABCG2-overexpressing cells. Furthermore, apatinib significantly inhibited the photoaffinity labeling of both ABCB1 and ABCG2 with iodoarylazidoprazosin in a concentration-dependent manner.

體內(nèi)研究：Apatinib inhibits the growth of a broad range of human tumor xenografts in a significant dose-dependent manner. Apatinib reverses ABCB1-mediated MDR in the nude mouse xenograft model. Apatinib significantly enhances the antitumor activity of doxorubicin in nude mice bearing K562/ADR xenografts.

產(chǎn)品信息訂購：

產(chǎn)品更多信息請(qǐng)進(jìn)入愛必信網(wǎng)站咨詢